MSD Continues to Seek Deals with Urgency
MSD has completed its $10 billion takeover of Verona Pharma, but is still looking for more acquisitions to enhance its pipeline, according to CEO Rob Davis.
"we need to do more…and we continue to look across all therapeutic areas."
Davis previously stated that MSD is seeking transactions worth up to $15 billion as it prepares for the loss of patent protection in 2028 for its top product, Keytruda (pembrolizumab), which contributed over $8 billion to its $17.3 billion in third-quarter revenues.
Author's summary: MSD seeks more deals after Verona Pharma takeover.
More News
- Gradam RTÉ Raidió na Gaeltachta 2025 to be presented to Mayo native - news - Western People
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- Patriots' Rhamondre Stevenson is out for Sunday's game vs Falcons
- Brendan Keaney on the dance sector's future strategy
- Adobe’s experimental AI tool can edit entire videos using one frame
- No Giannis, No Problem — Bucks Take Down Warriors as Antetokounmpo Steals the Show in Minion Costume
- Choose New Jersey President and CEO Mathews to Join PSEG
- Wemby’s Evolution Is Scary: Spurs Phenom Dominates Again, Leaves Heat Defenders Helpless
- Memoori: Hybrid Architectures, Cybersecurity Drive Change in Video Surveillance
- 0-12? Stephen Curry Drops Truth Bomb On Steve Kerr's Declaration After Losing To Bucks Without Giannis